Objective: The clinical usefulness of adriamycin (ADR) is restricted by the frequent induction of dose-dependent chronic cardiomyopathy. Previous studies on ADR cardiotoxicity have reported that the formation of free reactive oxygen radicals might be involved in ADR cardiotoxicity. Pyrrolidine dithiocarbamate (PDTC) is a potent antioxidant in vivo and in vitro. The present study was undertaken to examine the effects of PDTC on antioxidant enzymes in cardiomyopathy induced by ADR in rats. Methods: Thirty-two male Wistar rats were randomly divided into 4 groups: control, ADR, PDTC, and ADR+PDTC. After 30 days, myocardial histopathological and electron microscopic examinations were performed: the myocardial content of superoxide anion and lipid peroxides were examined; the myocardial total antioxygenation capability (T-AOC) and activity of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) were examined; myocardial GSH-Px, Mn-SOD and Cu,Zn-SOD gene expressions were examined by RT-PCR analysis, and the myocardial expression of GSH-Px, Mn-SOD and Cu,Zn-SOD proteins was assessed by Western blot analysis. Results: At 30 days, ADR-induced cardiomyopathy was confirmed by structural examination. The changes were prevented by PDTC. Myocardial superoxide anion and lipid peroxides were increased by ADR, and these changes were also inhibited by PDTC. ADR decreased myocardial T-AOC and the activity of GSH-Px and SOD, and these changes were likewise inhibited by PDTC. mRNA and protein expression of GSH-Px and Mn-SOD were depressed by ADR treatment and prevented by PDTC. Cu,Zn-SOD mRNA and protein levels were not significantly changed by ADR or PDTC. Conclusion: PDTC prevented ADR cardiomyopathy in rats by upregulating GSH-Px and SOD activation, which is associated with changes in the expression of GSH-Px and Mn-SOD transcript and protein levels.

Keywords:
Adriamycin, Pyrrolidine dithiocarbamate, Antioxygenation capability, total, Glutathione peroxidase, Superoxide dismutase
1.
Ahn SH, Han KH, Park JY, et al: Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma. Yonsei Med J 2004;45:847–858.
2.
Laufman LR, Spiridonidis CH, Jones JJ, et al: Phase I study of doxil and vinorelbine in patients with advanced malignancies. Cancer Invest 2004;22:344–352.
3.
Jones RL, Berry GJ, Rubens RD, et al: Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol 2004;5:575–577.
4.
Buzdar AU, Marcus C, Smith TL, Blumenschein GR: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985;55:2761–2765.
5.
Zhou S, Palmeira CM, Wallace KB: Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151–157.
6.
Koutinos G, Stathopoulos GP, Dontas I, et al: The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res 2002;22:815–820.
7.
Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK: Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol 2003;3:16.
8.
Mohamed HE, Asker ME, Ali SI, Fattah TM: Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. Pharm Pharmacol 2004;56:757–768.
9.
Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI: Alterations in myocardial cytoskeletal and regulatory protein expression following a single doxorubicin injection. J Cardiovasc Pharmacol 2003;41:788–794.
10.
Vitelli M, Filippelli A, Rinaldi B, et al: Effects of docosahexaenoic acid on [Ca(2+)](i) increase induced by doxorubicin in ventricular rat cardiomyocytes. Life Sci 2002;71:1905–1916.
11.
Zhou S, Heller LJ, Wallace KB: Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001;175:60–67.
12.
Liu X, Chen Z, Chua CC, et al: Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 2002;283:H254–H263.
13.
Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H: Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol 1999;43:227–232.
14.
Muller DN, Dechend R, Mervaala E, et al: NF-kB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193–201.
15.
Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37:781– 786.
16.
Schreck R, Meier B, Männel DN, et al: Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992;175:1181–1194.
17.
Hongli L, Hongyue G, Baogui S: Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 2007;114:159–165.
18.
Herman EH, Ferrans VJ, Myers CE, Van Vleet JF: Comparison of the effectiveness of (+/–)-1,2 bis (3.5-dioxopiperazinyl-1-yl) propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardio toxicity in beagles. Cancer Res 1985;45:276–281.
19.
Zhou S, Palmeira CM, Wallace KB: Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151–157.
20.
Xu MF, Tang PL, Qian ZM, Ashraf M: Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 2001;68:889–901.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.